Pin Wang, PhD

Professor

Image of Pin Wang, PhD
Is this your profile? Click to edit

Overview

The Wang laboratory focuses on an emerging field of “immunobioengineering” with the aim of employing engineering tools and principles to quantitatively understand the immune system in health and disease and to develop novel molecular and cellular immunotherapies by precisely modulating disease-specific immune responses. The ongoing research research projects include: 1) exploring various strategies to engineer virus-derived vector systems for dendritic cell-targeted vaccine delivery and oncolytic virus-based immunotherapy; 2) designing and optimizing cellular immunotherapy that is based on molecular engineering of chimeric antigen receptors (CARs); 3) exploring immune cells as drug carriers for targeted delivery of immunomodulatory drugs to enhance cancer immunotherapy; 4) exploring systems biology tools for modeling and understanding details of signaling pathways mediated by designer molecules such as chimeric antigen receptors to activate T cells; 5) developing engineering methods to improve adeno-associated virus (AAV)-based gene delivery. In this research laboratory, bioengineers collaborate with chemists, immunologists, computer scientists, and system biologists to directly address problems in translational immunology and develop and optimize innovative approaches to improve lives of patients suffering from cancer and infectious diseases.

Research Funding

  • In situ Redirection of T cell Specificity and Imaging of Targeted CAR Expression.
    NIH · R01EB017206 · Sep 1, 2013 – Aug 31, 2020 · Role: Co-Principal Investigator
  • SUPR Peptides to Inhibit Undruggable Cancer Target (PQ18)
    NIH · R01CA170820 · Sep 17, 2012 – Jun 30, 2017 · Role: Co-Principal Investigator
  • Targeting lentiviruses to infect chosen cells
    NIH · R01AI068978 · Feb 1, 2006 – Jan 31, 2012 · Role: Principal Investigator

Research Keywords

  • Cancer Immunotherapy
  • Immunoengineering
  • T Cell Engineering
  • Chimeric Antigen Receptor
  • Cancer Vaccine
  • Gene Therapy
  • Immuno-Oncology

Publications

  • High-fidelity AaCas12bMax enables the development of an engineered T cell therapy with enhanced safety and functional fitness. Mol Ther. 2025 Dec 03; 33(12):6101-6117.. View in PubMed
  • Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med. 2025 10 10; 6(10):100804.. View in PubMed
  • Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. Nat Commun. 2025 Feb 01; 16(1):1248.. View in PubMed
  • Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol. 2025 Mar; 43(3):329-344.. View in PubMed
  • Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy. Mol Ther. 2024 06 05; 32(6):1849-1874.. View in PubMed
  • Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering. Nat Commun. 2023 11 08; 14(1):6942.. View in PubMed
  • Advancing cell-based cancer immunotherapy through stem cell engineering. Cell Stem Cell. 2023 05 04; 30(5):592-610.. View in PubMed
  • Phospho-proteomics reveals that RSK signaling is required for proliferation of natural killer cells stimulated with IL-2 or IL-15. Cytokine. 2022 09; 157:155958.. View in PubMed
  • Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma. Theranostics. 2021; 11(10):4699-4709.. View in PubMed
  • ERK Activation in CAR T Cells Is Amplified by CD28-Mediated Increase in CD3ζ Phosphorylation. iScience. 2020 Apr 24; 23(4):101023.. View in PubMed